Intest Res.
2023 Jan;21(1):161-167. 10.5217/ir.2022.00006.
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
- Cheon JH
1 - Paridaens K2
- Awadhi SA3
- Begun J4
- Fullarton JR5
- Louis E6
- Magro F7,8
- Marquez JR9
- Moschen AR10
- Narula N11
- Rydzewska G12,13
- Dignass AU14
- Travis SP15
- Affiliations
-
- 1Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
- 2Ferring International Center, St-Prex, Switzerland
- 3Department of Gastroenterology, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates
- 4Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Australia
- 5Violicom Medical Limited, Aldermaston, UK
- 6Department of Hepato-Gastroenterology and Digestive Oncology, University and Centre Hospitalaire Univestitaire (CHU) Liège, Liège, Belgium
- 7Department of Biomedicine, Unit of Pharmacology and Therapeutics, University of Porto, Porto, Portugal
- 8Department of Gastroenterology, São João University Hospital Center, Porto, Portugal
- 9Instituto de Coloproctologia ICO Clinica Las Americas, Medellin, Colombia
- 10Department of Internal Medicine, Gastroenterology and Hepatology, Kepler University Hospital, Faculty of Medical, Johannes Kepler University, Linz, Austria
- 11Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada
- 12Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Subdivision, The Central Clinical Hospital of the Ministry of the Interior Affairs and Administration, Warsaw, Poland
- 13Collegium Medicum, Jan Kochanowski University, Kielce, Poland
- 14Department of Medicine I, Agaplesion Markus Hospital, Goethe-University, Frankfurt am Main, Germany
- 15NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
- KMID: 2539014
- DOI: http://doi.org/10.5217/ir.2022.00006
Figure
-
Fig. 1. Decision network among clinicians with >10 years’ experience (A) and with ≤10 years’ experience (B). 5-ASA, 5-aminosalicylic acid.
Reference
-
1. Dignass AU, Paridaens K, Al Awadhi S, et al. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scand J Gastroenterol. 2021; Dec. 21. [Epub]. https://doi.org/10.1080/00365521.2021.2015801.
Article2. Gisbert JP, Gomollón F, Hinojosa J, López San Román A. Adherence of gastroenterologists to European Crohn’s and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. J Crohns Colitis. 2010; 4:567–574.
Article3. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed webbased solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014; 20:2276–2285.4. Moshkovska T, Stone MA, Smith RM, Bankart J, Baker R, Mayberry JF. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011; 17:1874–1881.
Article5. Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis. 2021; 15:1184–1196.
Article6. Sood A, Ahuja V, Midha V, et al. Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intest Res. 2020; 18:355–378.
Article7. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021; 160:1570–1583.
Article
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
- Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
- Public Health Nurses' Decision Making Models and Their Knowledge Structure
- Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis
- A Case of Malignant Lymphoma in Patient with Ulcerative Colitis
